Matches in Nanopublications for { ?s ?p "[These results indicate that reduction of TNFR2+ T cells in AML postremission phase may result from combined azacitidine/lenalidomide therapy and may contribute to an improved clinical outcome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 3 of
3
with 100 items per page.
- NP748281.RACpmmhRU9ZiWnnB1XbyHHGheJnSPqZwi447eZ9KUntzs130_assertion description "[These results indicate that reduction of TNFR2+ T cells in AML postremission phase may result from combined azacitidine/lenalidomide therapy and may contribute to an improved clinical outcome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP748281.RACpmmhRU9ZiWnnB1XbyHHGheJnSPqZwi447eZ9KUntzs130_provenance.
- assertion description "[These results indicate that reduction of TNFR2+ T cells in AML postremission phase may result from combined azacitidine/lenalidomide therapy and may contribute to an improved clinical outcome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1175982.RAFBvz0NHgeDT2qXeq8bOGNBF50YW7YcGzFKJcQhHIM0g130_assertion description "[These results indicate that reduction of TNFR2+ T cells in AML postremission phase may result from combined azacitidine/lenalidomide therapy and may contribute to an improved clinical outcome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1175982.RAFBvz0NHgeDT2qXeq8bOGNBF50YW7YcGzFKJcQhHIM0g130_provenance.